224 related articles for article (PubMed ID: 37140750)
21. [Tolerability and Outcome of Neoadjuvant GS Therapy for Resectable Pancreatic Cancer].
Yamashita M; Shimizu J; Sato Y; Noma T; Hagihara K; Yanagimoto Y; Suzuki Y; Ikenaga M; Kawase T; Imamura H; Akagi K; Iwasawa S; Tomita N
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1411-1413. PubMed ID: 38303291
[TBL] [Abstract][Full Text] [Related]
22. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
Lee DH; Ha HI; Jang JY; Lee JW; Choi JY; Bang S; Lee CH; Kim WB; Lee SS; Kim SC; Kang BK; Lee JM
Eur Radiol; 2023 Sep; 33(9):5965-5975. PubMed ID: 36988715
[TBL] [Abstract][Full Text] [Related]
23. [The Clinical Efficacy of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Carcinoma--Report of Two Cases Treated by Curative Pancreatectomy with Portal Vein Resection after Neoadjuvant Chemotherapy].
Imamura T; Ikoma H; Morimura R; Hatakeyama T; Kosuga T; Konishi H; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Otsuji E
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2379-81. PubMed ID: 26805370
[TBL] [Abstract][Full Text] [Related]
24. Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors.
Masui T; Doi R; Kawaguchi Y; Sato A; Nakano K; Ito T; Anazawa T; Takaori K; Uemoto S
Surg Today; 2016 Nov; 46(11):1282-9. PubMed ID: 26860274
[TBL] [Abstract][Full Text] [Related]
25. Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre.
Itchins M; Arena J; Nahm CB; Rabindran J; Kim S; Gibbs E; Bergamin S; Chua TC; Gill AJ; Maher R; Diakos C; Wong M; Mittal A; Hruby G; Kneebone A; Pavlakis N; Samra J; Clarke S
Eur J Surg Oncol; 2017 Sep; 43(9):1711-1717. PubMed ID: 28688722
[TBL] [Abstract][Full Text] [Related]
26. Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma.
Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
Cancer Chemother Pharmacol; 2021 Jul; 88(1):109-120. PubMed ID: 33825991
[TBL] [Abstract][Full Text] [Related]
27. Examining neoadjuvant treatment candidates in resectable pancreatic cancer based on tumor-vessel interactions and CA 19-9 levels: a retrospective cohort study.
Jung HS; Han Y; Yun WG; Cho YJ; Lee M; Lee DH; Kwon W; Jang JY
Int J Surg; 2024 May; 110(5):2883-2893. PubMed ID: 38376856
[TBL] [Abstract][Full Text] [Related]
28. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
29. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
Dhir M; Zenati MS; Hamad A; Singhi AD; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
Ann Surg Oncol; 2018 Jul; 25(7):1896-1903. PubMed ID: 29761331
[TBL] [Abstract][Full Text] [Related]
30. A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma.
Furukawa T; Sasaki T; Ono Y; Kawano F; Takamatsu M; Mori C; Mie T; Yamada Y; Okamoto T; Takeda T; Kasuga A; Matsuyama M; Ozaka M; Takahashi Y; Sasahira N
Clin J Gastroenterol; 2021 Oct; 14(5):1571-1577. PubMed ID: 34255287
[TBL] [Abstract][Full Text] [Related]
31. Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis.
Yoon MS; Lee HS; Kang CM; Lee WJ; Keum J; Sung MJ; Kim SS; Park MS; Jo JH; Chung MJ; Park JY; Park SW; Song SY; Hwang HK; Bang S
Gut Liver; 2022 Jan; 16(1):118-128. PubMed ID: 34140428
[TBL] [Abstract][Full Text] [Related]
32. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial).
Maurel J; Sánchez-Cabús S; Laquente B; Gaba L; Visa L; Fabregat J; Povés I; Roselló S; Díaz-Beveridge R; Martín-Richard M; Rodriguez J; Sabater L; Conill C; Cambray M; Reig A; Ayuso JR; Valls C; Ferrández A; Bombí JA; Ginés A; García-Albéniz X; Fernández-Cruz L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):935-943. PubMed ID: 30225601
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial.
Reni M; Balzano G; Zanon S; Zerbi A; Rimassa L; Castoldi R; Pinelli D; Mosconi S; Doglioni C; Chiaravalli M; Pircher C; Arcidiacono PG; Torri V; Maggiora P; Ceraulo D; Falconi M; Gianni L
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):413-423. PubMed ID: 29625841
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant Treatment for Pancreatic Cancer.
Raufi AG; Manji GA; Chabot JA; Bates SE
Semin Oncol; 2019 Feb; 46(1):19-27. PubMed ID: 30630600
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
Janssen QP; O'Reilly EM; van Eijck CHJ; Groot Koerkamp B
Front Oncol; 2020; 10():41. PubMed ID: 32083002
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer - A Matched-Pair Analysis.
Timmermann L; Rosumeck N; Klein F; Pratschke J; Pelzer U; Bahra M; Malinka T
Anticancer Res; 2019 Oct; 39(10):5781-5787. PubMed ID: 31570482
[TBL] [Abstract][Full Text] [Related]
37. Vasculitis, CA19-9, and Perineural Invasion Differentially Predict Response and Surgical Outcome in Pancreatic Ductal Adenocarcinoma.
Piper M; Ross RB; Hu J; Watanabe S; Knitz M; Mehrotra S; Shulick R; Chiaro MD; Karam SD
Int J Radiat Oncol Biol Phys; 2023 Jul; 116(3):627-639. PubMed ID: 36599398
[TBL] [Abstract][Full Text] [Related]
38. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Macedo FI; Ryon E; Maithel SK; Lee RM; Kooby DA; Fields RC; Hawkins WG; Williams G; Maduekwe U; Kim HJ; Ahmad SA; Patel SH; Abbott DE; Schwartz P; Weber SM; Scoggins CR; Martin RCG; Dudeja V; Franceschi D; Livingstone AS; Merchant NB
Ann Surg; 2019 Sep; 270(3):400-413. PubMed ID: 31283563
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer.
Alva-Ruiz R; Yohanathan L; Yonkus JA; Abdelrahman AM; Gregory LA; Halfdanarson TR; Mahipal A; McWilliams RR; Ma WW; Hallemeier CL; Graham RP; Grotz TE; Smoot RL; Cleary SP; Nagorney DM; Kendrick ML; Truty MJ
Ann Surg Oncol; 2022 Mar; 29(3):1579-1591. PubMed ID: 34724125
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: Intention-to-treat analysis compared with upfront surgery.
Inoue Y; Saiura A; Oba A; Ono Y; Mise Y; Ito H; Sasaki T; Ozaka M; Sasahira N; Takahashi Y
J Hepatobiliary Pancreat Sci; 2021 Feb; 28(2):143-155. PubMed ID: 33058515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
